B7-H3 regulates osteoclast differentiation via type I interferon-dependent IDO induction by Oh, Younseo et al.
ARTICLE OPEN
B7–H3 regulates osteoclast differentiation via type I interferon-
dependent IDO induction
Younseo Oh1,2, Robin Park3, So Yeon Kim1,4, Sung-ho Park5, Sungsin Jo1, Tae-Hwan Kim 1,4,6✉ and Jong Dae Ji 2✉
© The Author(s) 2021
While their function, as immune checkpoint molecules, is well known, B7-family proteins also function as regulatory molecules in bone
remodeling. B7–H3 is a receptor ligand of the B7 family that functions primarily as a negative immune checkpoint. While the regulatory
function of B7–H3 in osteoblast differentiation has been established, its role in osteoclast differentiation remains unclear. Here we show
that B7–H3 is highly expressed in mature osteoclasts and that B7–H3 deficiency leads to the inhibition of osteoclastogenesis in human
osteoclast precursors (OCPs). High-throughput transcriptomic analyses reveal that B7–H3 inhibition upregulates IFN signaling as well as
IFN-inducible genes, including IDO. Pharmacological inhibition of type-I IFN and IDO knockdown leads to reversal of B7–H3-deficiency-
mediated osteoclastogenesis suppression. Although synovial-fluid macrophages from rheumatoid-arthritis patients express B7–H3,
inhibition of B7–H3 does not affect their osteoclastogenesis. Thus, our findings highlight B7–H3 as a physiologic positive regulator of
osteoclast differentiation and implicate type-I IFN–IDO signaling as its downstream mechanism.
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INTRODUCTION
Osteoclasts are bone-resorptive cells derived from hematopoietic
cells of the myeloid lineage that are central to physiological and
pathological bone remodeling [1, 2]. The differentiation of OCPs
into mature osteoclasts is triggered by stimulation with
macrophage-colony-stimulating factor (M-CSF) and receptor
activator of nuclear-factor kappa-B ligand (RANKL) [3]. Physiolo-
gically, osteoclast-mediated bone resorption and osteoblast-
mediated bone formation maintain homeostasis [4]. On the other
hand, in the pathological setting, increased osteoclast activity
drives inflammatory bone destruction characteristic of certain
chronic autoimmune diseases such as rheumatoid arthritis (RA)
[5, 6]. Consequently, osteoclasts must be tightly regulated to
suppress bone destruction and hence represent a crucial
therapeutic target in inflammatory bone disorders.
The B7 superfamily of proteins comprises immunoregulatory
receptor ligands that act as either costimulatory or co-inhibitory
immune checkpoints by primarily regulating the activity of T cells
[7]. Among them, B7–H3 is a type-I transmembrane protein, which
exists in two separate isoforms that are determined by its
extracellular domain. In humans, the extracellular domain consists
of either one pair (2Ig–B7–H3) or two identical pairs (4Ig–B7–H3).
While both isoforms are found in the intracellular compartment,
only the 4Ig–B7–H3 isoform is expressed on the cell surface in
human mononuclear cells [8]. The function of B7–H3 was
previously thought to be a costimulatory checkpoint molecule
but it has now been established as primarily a co-inhibitory
immune-checkpoint molecule. Furthermore, B7–H3 is abundantly
expressed in the synovium of RA patients with relative over-
expression in synovial macrophages compared with their periph-
eral monocytes. Moreover, its expression is closely linked to
clinically relevant disease-activity markers, such as C-reactive
protein, erythrocyte-sedimentation rate, and Disease Activity
Score-28 (DAS28), suggesting that B7–H3 is implicated in RA
pathogenesis [9–11].
Certain members of the B7 family such as B7.1/B7.2 (CD80/86)
and B7–H2 (ICOS ligand) act as regulatory molecules in osteoclast
differentiation. Unlike in their function as immune checkpoints in
which they utilize a forward-signaling mechanism to propagate
their effects, B7.1/B7.2 (CD80/86) and B7–H2 (ICOS ligand) inhibit
osteoclast differentiation using a distinct reverse-signaling
mechanism [12, 13]. Furthermore, the dual role of immune
response and the regulation of bone remodeling has also been
established for B7–H3, which has been implicated in the
regulation of osteoblast differentiation [14]. However, whether
B7–H3 is implicated in the regulation of osteoclast differentiation
remains unknown. Therefore, we aimed to elucidate the function
of B7–H3 and establish B7–H3 as a regulatory mechanism in
osteoclast differentiation in RA.
MATERIALS/SUBJECTS AND METHODS
Materials
Recombinant human M-CSF and soluble RANKL were purchased
from PeproTech, NJ, USA. Recombinant human M-CSF receptor/Fc
chimera and B7–H3–Fc were respectively obtained from Sino
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Biological, PA, USA and R&D System, MN, USA. Human IgG
purchased from Millipore was used as the control for B7–H3–Fc.
Human IFN-αR2-receptor antibody was obtained from PBL Assay
Science. Human IFN-γ antibody, IL-27 antibody, and recombinant
human IFN-β, IFN-γ, and IL-27 were obtained from R&D System.
Mouse IgG2a purchased from R&D system was used as the isotype
control. 1-D-MT, 1-L/D-MT, and CH223191 were purchased from
Sigma, MA, USA.
Cell isolation
Human peripheral blood monocytes (PBMCs) were isolated from
the blood of healthy donors using Ficoll gradient centrifugation
(GE Healthcare, IL, USA). Monocytes were purified from PBMCs
using CD14-positive magnetic beads (Miltenyi Biotec, CA, USA)
according to the manufacturer’s instructions. Inflammatory RA or
ankylosing-spondylitis (AS) macrophages were purified by positive
selection using CD14 magnetic beads from synovial-fluid mono-
nuclear cells. The experiments using human cells were approved
by the Ethics Committee of Hanyang University Hospital for
Rheumatic Disease (IRB No. 2008-09-001, 2017-05-003). All healthy
volunteers and RA and AS patients provided their written
informed consent to participate in this study.
Mice
Wild-type (WT) and B7–H3-knockout (KO) (B7–H3−/−) mice with
the C57BL/6 background were purchased from Cyagen Bios-
ciences. Eight-week-old mice were housed in a specific pathogen-
free facility. All experiments were approved by the Institutional
Animal Care and Use Committee at Hanyang University (HY-
IACUC-2020-0131).
Osteoclast differentiation
For human osteoclast differentiation, monocytes of human PBMC
origin were incubated with 20 ng/ml M-CSF for two days to derive
OCPs, which were further cultured in 20 ng/ml M-CSF and 40 ng/
ml RANKL for an additional six days. For mouse osteoclast
differentiation, whole bone marrow cells were isolated from
femurs and tibias of mice. The cells were cultured in 10 ng/ml
M-CSF for one day. Nonadherent cells were then cultured with
20 ng/ml M-CSF for one day to obtain bone marrow-derived
macrophages (BMMs). The attached cells, which are capable of
osteoclast differentiation, were seeded and cultured with 50 ng/ml
M-CSF and 100 ng/ml RANKL for four days. Cytokines were
replenished every three days. The cells were cultured in α-MEM
(Gibco, MT, USA) supplemented with 10% FBS (Gibco, MT, USA).
The cells were fixed with 4% paraformaldehyde and stained for
TRAP using Acid Phosphatase Leukocytes diagnostic kit (Cosmo
Bio, CA, USA), as recommended by the manufacturer. Multi-
nucleated (>3 or 10 nuclei in human osteoclasts, >10 nuclei in
mouse osteoclasts) TRAP-positive cells were counted in duplicate
wells of 48-well plates. Microphotographs of staining were
observed at original magnification X100.
Transfection
Before transfection, 40 ng/ml M-CSF was added to CD14-positive
cells from PBMCs or RA synovial-fluid mononuclear cells for three
days. For RNA interference, the OCPs were transfected with ON-
TARGET plus SMARTpool siRNAs specific for B7–H3, IDO, and AhR
(Dharmacon). ON-TARGET plus Non-targeting Pool was used as
the control. To overexpress B7–H3, the OCPs were transfected with
human pCMV3–B7–H3 ORF-expression plasmid and pCMV3-
negative control vector (Sino Biological, PA, USA). For transfection,
lipofectamine 3000 (Invitrogen, CA, USA) was used according to
the manufacturer’s instructions. After siRNA or plasmid transfec-
tion, OCPs were cultured in α-MEM with 40 ng/ml M-CSF and
80 ng/ml RANKL for seven days to generate mature osteoclasts. Of
note, M-CSF 20 ng/mL was used as the default concentration,
while the 40 ng/mL concentration was used to increase the
transfection efficiency.
Actin-ring staining
At the end of the culture period, the cells were fixed with 4%
paraformaldehyde, permeabilized in 0.1% Triton X-100 for 5 min,
and then stained with FITC-conjugated phalloidin (Sigma-Aldrich)
for 1 h at 37 °C.
Bone-resorption assays
After siRNA transfection, OCPs were plated on dentin slices
(Immunodiagnostic Systems, UK) in 96-well plates and cultured
with M-CSF and RANKL. The cells on the dentin disc were removed
by washing with 70% ethanol. The dentin discs were rinsed with
water and immersed in 1% toluidine blue O (Sigma-Aldrich) to
stain resorption pits formed by osteoclasts.
Bone-density imaging and analysis
Femurs from WT and B7–H3 KO male mice were fixed in 4%
paraformaldehyde for micro-CT analysis. Trabecular and cortical
morphometry within the femur were quantified using a benchtop
cone-beam-type in vivo animal scanner (SKYSCAN1172 micro-CT,
Bruker microCT, Belgium). Samples were imaged with the
following settings: 60 kVp, 166 μA, and an aluminum 0.25-mm-
thick filter. The pixel size was 9.0 μm and the rotation step was
0.6°. The cross-sectional images were reconstructed using a
filtered back-projection algorithm (NRecon software, Bruker
microCT, Belgium). Trabecular morphometry used the following
measurement parameters: bone-volume fraction (BV/TV), trabe-
cular thickness (Tb. Th), trabecular number (Tb. No), and trabecular
spacing (Tb. Sp).
Quantitative real-time PCR
Total RNA was extracted from the cells using Trizol (Invitrogen)
according to the manufacturer’s instructions. The RNA was
reverse-transcribed using reverse transcriptase (Invitrogen) and
random hexamers (Invitrogen). qPCR was performed in triplicate
with Fast SYBR Green Master Mix (Bioline, London, UK) using
CFX96 (Bio-Rad, CA, USA). The primers used for qPCR are provided
in Supplementary Table S1.
Immunoblotting
Total cell extracts were obtained using 1X RIPA lysis buffer (Cell
Signaling, MA, USA) containing 1X proteinase-inhibitor cocktail
(Calbiochem, CA, USA), 1 mM PMSF (Sigma-Aldrich), and 1X
phosphatase-inhibitor (Cell Signaling, MA, USA). Cell lysates were
fractionated on 10% SDS-polyacrylamide gels, transferred to
nitrocellulose membranes (GE Healthcare Life Sciences), and
incubated with specific primary antibodies. Immunoblotting was
performed with the following antibodies: B7–H3 (R&D System);
c-Fos (Abcam, MA, USA); NFATc1 (BD Biosciences, CA, USA); c-Fms,
IκBα, p-p38 MAPK, p-p44/42 MAPK, p44/42 MAPK, IDO, p-STAT1,
STAT1, AhR, β-actin, and GAPDH (Cell Signaling, MA, USA); RANK,
p38α, and iNOS (Santa Cruz, CA, USA). Secondary antibodies
(Jackson ImmunoResearch) were incubated before adding the ECL
substrate (Invitrogen). For quantitative analysis of protein expres-
sion, the optical densities of the blot bands were measured using
the Image J software.
Flow cytometry
Cells were washed with 1X PBS containing 0.5% bovine serum
albumin and 0.1% sodium azide and then incubated in Fc-
receptor-blocking reagent (Miltenyi Biotec). Cells were stained
with APC-conjugated anti-human B7–H3 (Biolegend, CA, USA) and
analyzed by using FACS Canto flow cytometer (BD Biosciences, CA,
USA). The flow-cytometric data were analyzed using FlowJo
software (Treestar, OR, USA).
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Cell-proliferation assay
Cells were seeded in 96-well plates and added Ez-cytox viability kit
reagent (DoGen, Kyoto, Japan) for the indicated number of days.
The cells were incubated for 1 h at 37°C to allow the Ez-cytox
viability kit reagent to metabolize to formazan. Absorbance was
measured at 450 nm using a microplate reader and culture
medium was used as a blank.
RNA sequencing
Total RNA concentration was calculated by Quant-IT RiboGreen
(Invitrogen). To assess the integrity of the total RNA, samples are
run on the TapeStation RNA screentape (Agilent, CA, USA). Only
high-quality RNA preparations, with RIN greater than 7.0, were
used for RNA library construction. A library was independently
prepared with total RNA (1ug) for each sample by TruSeq
Stranded mRNA Sample Prep Kit (Illumina, CA, USA). The libraries
were quantified using KAPA Library Quantification kits for Illumina
Sequencing platforms according to the qPCR Quantification
Protocol (Kapa Biosystems, MA, USA) and qualified using the
TapeStation D1000 ScreenTape (Agilent, CA, USA). Indexed
libraries were then submitted to an Illumina NovaSeq (Illumina,
CA, USA), and the paired-end (2 × 100 bp) sequencing was
performed by the Macrogen Incorporated. Differentially expressed
genes between B7–H3-deficient and control transcriptomes were
identified using DESeq2 using a p-value <0.05 as the significance
threshold and enriched pathways were identified using IPA.
Statistical analysis
The results are expressed as mean ± SD. The Mann–Whitney U test
was used to calculate statistical significance. Statistical significance
was defined as *P < 0.05, **P < 0.01, ***P < 0.001. Columns and
error bars in figures indicate the mean values and standard errors
for at least three independent experiments.
RESULTS
B7–H3 is expressed during human osteoclast differentiation
To confirm the presence of B7–H3 expression during human
osteoclast differentiation, we induced PBMCs from healthy
controls (HC) to undergo osteoclastogenesis using M-CSF and
RANKL (Fig. 1A). Expression of the mRNA, protein, and cell-surface
protein levels of B7–H3 gradually increased during osteoclast
differentiation (Fig. 1B, C, D). Since the main form of cell-surface
protein on human mononuclear cells is the 4Ig–B7–H3 isoform,
our experiments involving B7–H3-surface proteins hereafter refer
to this isoform. Osteoclast differentiation was confirmed using the
Fig. 1 B7–H3 expression is increased during differentiation of human osteoclasts. A A schematic diagram outlining the process of
osteoclast differentiation from human PBMCs. B B7–H3 mRNA expression during human osteoclast differentiation measured using RT-qPCR. C
Whole-cell lysates were immunoblotted with B7–H3, c-Fos, and NFATc1 Abs. D At days 0, 2, and 8, the cell-surface B7–H3 expression was
assessed by flow cytometry (solid line: monocytes; dashed line: OCPs or mature osteoclasts; gray shaded: isotype control). E, F OCPs were
cultured as described in Fig. 1A. OCPs were incubated with M-CSF (20 ng/ml) in the presence or absence of recombinant human M-CSF
receptor/Fc chimera (sM-CSF R) overnight. The expression of B7–H3 and RANK mRNA was measured using RT-qPCR and the expression of
B7–H3 protein was detected using Western blot. G, H OCPs were cultured with M-CSF (20 ng/ml) in the presence of RANKL (40 ng/ml) for one
or three days. RT-qPCR and Western blot were performed to detect the expression of B7–H3. (B, E, G) mRNA levels were normalized with
GAPDH expression.
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expression of c-Fos and NFATc1 (Fig. 1C). We found that M-CSF
blockade partially abolished M-CSF-induced B7–H3 mRNA and
protein expression (Fig. 1E, F). Furthermore, RANKL upregulated
B7–H3 protein expression at day 3 without affecting changes in its
mRNA levels (Fig. 1G, H). Taken together, these findings confirm
that B7–H3 expression is induced upon osteoclast differentiation.
B7–H3 deficiency inhibits human osteoclast differentiation
Next, we showed that B7–H3 knockdown was associated with a
reduction of multinucleated TRAP-positive cells, decreased actin-
ring formation, and suppressed osteoclast resorption of dentin
discs (Fig. 2A). B7–H3 siRNA activity was confirmed in OCPs (Fig.
2B, D, E). Reduced osteoclast formation was not a consequence of
Y. Oh et al.
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changes in cell viability (Supplementary Fig. 1A). Furthermore,
B7–H3 knockdown significantly suppressed RANKL-induced osteo-
clast-related gene expression such as cathepsin K (CTSK), tartrate-
resistant acid phosphatase (TRAP), dendritic cell-specific trans-
membrane protein (DC-STAMP), and β3 integrin (ITGB3), as well as
the protein expression of NFATc1 (Fig. 2C, E). Additionally, c-Fms
was slightly reduced at day 0 without any changes in RANK
expression (Fig. 2D, E). While B7–H3 knockdown slightly enhanced
the phosphorylation of p38, it did not alter ERK, MAPK, and IκBα
levels (Supplementary Fig. 2A). Next, we confirmed that the
soluble recombinant B7–H3, protein (B7–H3–Fc) strongly sup-
pressed the formation of RANKL-induced TRAP-positive cells in a
dose-dependent manner (Fig. 2F, G) and significantly decreased
the expression of CTSK, TRAP, DC-STAMP, and ITGB3 as well as
NFATc1 (Fig. 2H, I). The inhibitory effect of B7–H3, depending on
the timing or duration of exposure, was assessed and B7–H3–Fc
was found to decrease the number of osteoclasts, regardless of
the phase of differentiation. (Supplementary Fig. 2B). Cell viability
remained unaffected by B7–H3–Fc (Supplementary Fig. 1B). Taken
together, the effects of B7–H3–Fc were consistent with that of
B7–H3 siRNA, further supporting the regulatory function of B7–H3
in human osteoclastogenesis. On the other hand, micro-CT
analysis of B7–H3 KO mice showed that there were no between-
group differences in trabecular bone volume, thickness, number,
spacing (Supplementary Fig. 3A, B). B7–H3 KO BMMs demon-
strated reduced sizes of multinucleated TRAP-positive osteoclasts,
actin-ring formation, and osteoclast-related genes compared with
their wild-type (WT) counterparts. No between-group differences
were seen in the number of osteoclasts (Supplementary Fig. 3C,
D). These findings highlight the differences in the mechanism of
B7–H3 in regulating osteoclast differentiation in mice and
humans.
B7–H3 deficiency activates IFN signaling
Next, we searched for potential downstream mediators using
transcriptomic analyses in B7–H3 siRNA-transfected OCPs and
identified differentially expressed genes, many of which encode
inflammatory cytokines (Fig. 3A, Supplementary Table S2). Among
these genes, IPA revealed a pathway enrichment in IFN signaling
(Fig. 3B) and top upstream-regulator predictions showed elevated
activities of IFNs and STAT1 (Fig. 3C). Accordingly, B7–H3-deficient
OCPs demonstrated upregulation of STAT1-activating and -depen-
dent genes such as IFNs and IL-27 (Fig. 3D). These results were
confirmed via RT-qPCR (Fig. 3E, F). Then, using B7–H3-expressing
plasmid transfection, we showed that B7–H3 overexpression
suppressed the expression of IFNB, IFNG, IL-27A, and IL-27B as
well as IFN-response genes (Supplementary Fig. 4A–C). Also, we
found that B7–H3 knockdown induced CD80/86 expression in the
context of osteoclastogensis (Fig. 3G). Taken together, these
results implicate IFNs and IL-27 as potential downstream
mediators of B7–H3 in the regulation of osteoclast differentiation.
The inhibition of osteoclastogenesis is restored by the
addition of a neutralizing anti-IFN-αR2 antibody in B7–H3-
deficient OCPs
We then cultured B7–H3 siRNA-transfected OCPs in the presence
of neutralizing antibodies to IFN-γ, IL-27, and IFN-αR2 to confirm
the role of IFNs and IL-27 as downstream mediators. Whereas anti-
IFN-γ and anti-IL-27 failed to affect osteoclast differentiation,
including the expression of NFATc1, anti-IFN-αR2 successfully
restored osteoclastogenesis inhibition in B7–H3 siRNA-transfected
OCPs (Fig. 4A, B). We focused our investigations on the effect of
IFN-β since previous studies showed that IFN-β, and not IFN-α,
inhibits RANKL-induced osteoclastogenesis. IFN-β dose-
dependently suppressed osteoclast differentiation, while anti-
IFN-αR2 successfully reversed this IFN-β-mediated suppression of
osteoclastogenesis (Fig. 4C–E). Thus, these findings indicate that
type-I IFNs rather than type-II IFNs or IL-27 are the most likely
candidate downstream mediators of B7–H3 in the regulation of
osteoclastogenesis.
The inhibition of osteoclastogenesis in B7-H3-deficient OCPs
is not mediated by previously identified mechanisms
modulated by IFN-β
Next, we investigated the downstream mediators of type-I IFNs.
We found that B7–H3 knockdown inhibited c-Fos expression.
However, the c-Fos protein was only weakly inhibited and
therefore unlikely to mediate B7–H3 siRNA-mediated osteoclasto-
genesis inhibition (Fig. 5A). We showed that B7–H3 siRNA
upregulated SOCS1 expression, which is inconsistent with the
previous studies showing that IFN-β-mediated osteoclastogenesis
inhibition occurs through SOCS1 downregulation via miR-155
induction (Fig. 5B). We found that although the iNOS mRNA levels
increased, its protein levels did not increase following B7–H3
knockdown (Fig. 5C). Taken together, c-Fos, SOCS1, and iNOS are
unlikely candidate downstream mediators of type-I IFN-mediated
osteoclastogenesis inhibition in B7–H3-deficient OCPs.
IDO induction mediates osteoclastogenesis inhibition in
B7–H3-deficient OCPs
Next, we found that IDO protein expression and STAT1
phosphorylation were dramatically induced in B7–H3-deficient
and B7–H3 Fc-treated OCPs and that B7–H3 deletion led to a
sustained constitutive expression of IDO throughout osteoclasto-
genesis (Fig. 6A, Supplementary Fig. 5A, B). Conversely, B7–H3
overexpression suppressed IDO protein expression and STAT1
phosphorylation in OCPs (Fig. 6B). Moreover, IDO knockdown
reversed osteoclastogenesis inhibition and the suppression of
osteoclastogenesis-related genes as well as NFATc1 protein
expression (Fig. 6C–E). Furthermore, anti-IFN-αR2 successfully
reversed the IDO induction caused by B7–H3 siRNA and these
results were confirmed by demonstrating that type-I IFNs
increased IDO expression and reduced multinucleated TRAP-
Fig. 2 B7–H3 deficiency suppresses human osteoclast differentiation. A Prior to transfection, M-CSF (40 ng/ml) was added to monocyte
culture for three days. OCPs were transiently transfected with B7–H3-specific siRNA, control siRNA (40 nM), or neither, and then induced to
differentiate using M-CSF (40 ng/ml) and RANKL (80 ng/ml) for seven days. After staining for TRAP expression, the TRAP-positive
multinucleated cells were counted as osteoclasts (>3 or 10 nuclei). Actin rings in osteoclasts were stained with FITC-phalloidin and bone-
resorption pits were stained with 1% toluidine blue O in 0.5% sodium borate (scale bar, 200 μm). B Cell-surface B7–H3 expression was
measured using flow cytometry at day 0. The representative histograms are shown (solid line: control siRNA; dashed line: B7-H3-specific siRNA;
gray shaded: isotype control). C The expression of mature osteoclast markers, CTSK, TRAP, DC-STAMP, and ITGB3, was analyzed using RT-qPCR
at day 7. D The expression of B7–H3, CSF1R, and RANK mRNA during osteoclast differentiation was detected using RT-qPCR. E Whole-cell
lysates were immunoblotted with B7–H3, NFATc1, c-Fms and RANK antibodies. F Monocytes were cultured with M-CSF (20 ng/ml) for two
days. OCPs were further incubated with M-CSF (20 ng/ml) and RANKL (40 or 20 ng/ml) in the presence of B7–H3–Fc (5 μg/ml) or human IgG for
six days. G OCPs were cultured with M-CSF (20 ng/ml) and RANKL (20 ng/ml) in the presence of B7–H3–Fc (10, 5, and 2.5 μg/ml) or human IgG
for six days. F, G TRAP staining was performed and the number of TRAP-positive multinucleated cells per well were counted as osteoclasts
(scale bar, 200 μm). H OCPs were cultured with M-CSF (20 ng/ml) and RANKL (20 ng/ml) in the presence of B7–H3–Fc (5 μg/ml) or human IgG.
The expression of the mature osteoclast markers, CTSK, TRAP, DC-STAMP, and ITGB3, was analyzed at day 8 using RT-qPCR. (I) Whole-cell
lysates were immunoblotted with NFATc1 antibody. C, D, H The mRNA levels were normalized relative to GAPDH expression.
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Fig. 3 B7–H3 deficiency activates IFN signaling. A M-CSF (40 ng/ml) was added to monocyte culture for three days and then the cells were
transiently transfected with B7–H3-specific siRNA or control siRNA (40 nM) for one day. Gene expression was analyzed using RNA sequencing
(RNA-seq) and depicted using a volcano plot. The x axis indicates the log 2-fold changes in gene expression, such that data points plotted to
the right indicate increased and left indicates decreased expression, respectively. B A simple bar graph depicting the 11 topmost enriched
pathways. Higher values on the x axis indicate greater statistical significance. C A bar graph depicting the top 10 most upregulated (red) and
downregulated (blue) potential upstream genes derived from Ingenuity Pathway Analysis (IPA). D Heatmap of RNA-seq CPM values for STAT1-
activating and -dependent genes in B7–H3-deficient OCPs. RNA-seq data from 2 biological replicates were used. E, F, G Differentially
expressed genes were analyzed using RT-qPCR. The mRNA levels were normalized relative to GAPDH expression.
Y. Oh et al.
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positive cell formation (Fig. 6F, G). However, IFN-β-mediated
osteoclast inhibition was not reversed by IDO knockdown (Fig. 6H,
I). Therefore, while osteoclastogenesis inhibition in the context of
B7–H3 knockdown appears to be mediated at least in part by type-
I IFN-mediated IDO induction, our findings raise the possibility that
additional unidentified mechanisms may be present.
IDO-mediated inhibition of osteoclastogenesis in B7–H3-
deficient OCPs is independent of tryptophan metabolism
We found that multinucleated TRAP-positive osteoclasts were
strongly suppressed by kynurenine (Fig. 7A). We then cultured
B7–H3 siRNA-transfected OCPs in the presence of 1-MT (IDO
inhibitor), exogenous tryptophan, and CH223191 (AhR inhibitor).
Y. Oh et al.
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1-MT and exogenous tryptophan failed to reverse B7–H3 siRNA-
mediated osteoclastogenesis inhibition whereas CH223191
altered multinucleated osteoclast morphology without causing
changes in the number of cells (Fig. 7B–D). Furthermore, AhR
siRNA restored B7–H3 deficiency-mediated suppression of osteo-
clastogenesis (Fig. 7E, F). In one out of five of the repeat
experiments, AhR siRNA failed to restore osteoclastogenesis
inhibition, which was concluded to be due to the unsuccessful
suppression of IDO by AhR siRNA (Supplementary Fig. 6A, B).
Nonetheless, AhR siRNA alone enhanced IDO expression in OCPs.
Taken together, these results suggest that the AhR-associated
signaling pathway may be involved in B7–H3-mediated
osteoclastogenesis.
B7–H3 deficiency does not affect osteoclast differentiation in
RA synovial-fluid macrophages
We then examined the B7–H3-expression levels in RA synovial-
fluid macrophages compared with HC PBMCs and ankylosing-
spondylitis (AS) synovial-fluid macrophages. B7–H3 mRNA levels
were higher in RA synovial macrophages compared with HC
PBMCs and no significant differences in B7–H3 mRNA levels were
found between AS synovial-fluid macrophages and HC PBMCs
(Fig. 8A). Consistently, B7–H3 protein levels were also higher in RA
synovial-fluid macrophages (Fig. 8B). In contrast to HC PBMCs,
B7–H3 knockdown did not affect RA synovial macrophage
osteoclast differentiation and the expression of osteoclast-
related genes as well as NFATc1 protein (Fig. 8C–E). Furthermore,
IDO expression and STAT1 phosphorylation, as well as IFN-
response gene expression, remained largely unchanged by B7–H3
knockdown and by IFN-β stimulation in RA synovial-fluid
macrophages (Fig. 8F–H). Taken together, these results indicate
that B7–H3 has differential effects on osteoclast differentiation in
RA synovial-fluid macrophages compared with PBMCs.
DISCUSSION
In summary, we found that inhibition of B7–H3 using B7–H3 siRNA
and soluble B7–H3–Fc treatment led to osteoclastogenesis
Fig. 4 The inhibition of osteoclastogenesis is restored by the addition of a neutralizing anti-IFN-αR2 antibody in B7–H3-deficient OCPs. A
M-CSF (40 ng/ml) was added in monocyte culture for three days. OCPs were transiently transfected with B7–H3-specific siRNA or control siRNA
(20 nM) and then induced to differentiate using M-CSF (40 ng/ml) and RANKL (80 ng/ml) in the presence of neutralizing antibodies for IFN-αR2,
IFN-γ, or IL-27 for seven days. B Whole-cell lysates were immunoblotted with B7–H3 and NFATc1 Abs. C Monocytes were cultured with M-CSF
(20 ng/ml) in the presence of IFN-β (0.1 and 1 ng/ml) or distilled water for two days and then were further incubated with M-CSF (20 ng/ml)
and RANKL (40 ng/ml) in the presence of recombinant IFN-β or distilled water for six days. OCPs, cultured with M-CSF (20 ng/ml) for two days,
were induced to differentiate using M-CSF (20 ng/ml) and RANKL (40 ng/ml) in the presence of recombinant IFN-β (0.1 and 1 ng/ml) or distilled
water for an additional six days. D OCPs were induced to differentiate using M-CSF (20 ng/ml) and RANKL (40 ng/ml) in the presence of anti-
IFN-αR2 and recombinant IFN-β (1 ng/ml) for six days. (A, C, D) TRAP staining was performed and the number of TRAP-positive multinucleated
cells per well were counted (scale bar, 200 μm). E Monocytes were incubated with or without neutralizing antibodies (2 μg/ml) against IFN-
αR2, IFN-γ, or IL-27 for 1 h. Control antibodies were used at the equal concentration. At the end of the duration of culture, the cells were
treated with recombinant IFN-β (10 ng/ml) or IFN-γ (10 ng/ml) for 10m or recombinant IL-27 (50 ng/ml) for one day. The expression of
phospho-STAT1 (PY701), STAT1, and IDO protein was evaluated via Western blot.
Fig. 5 B7–H3 deficiency-mediated type-I IFN-dependent osteoclastogenesis inhibition is independent of c-Fos, iNOS, and SOCS1. A, B
M-CSF (40 ng/ml) was added to monocyte culture for three days. OCPs that were transiently transfected with B7–H3-specific siRNA or control
siRNA (40 nM) were induced to differentiate using M-CSF (40 ng/ml) and RANKL (80 ng/ml) for seven days. The expression of B7–H3, c-Fos and
iNOS protein during osteoclast differentiation was detected via Western blot. The bar graphs show the densitometry analyses of the gels
depicted relative to the internal control at day 7 of differentiation. B, C OCPs were transiently transfected with B7–H3-specific siRNA or control
siRNA (40 nM) for one day. The expression of SOCS1 and iNOS mRNA was analyzed using RT-qPCR. The mRNA levels were normalized relative
to GAPDH expression.
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inhibition and to increased type-I IFN signaling, STAT1 activation,
and IDO induction. In addition, type-I IFN and IDO suppression
reversed osteoclastogenesis inhibition, while type-I IFN blockade
suppressed B7–H3 siRNA-mediated IDO induction. Taken together,
we add to the emerging paradigm in which immune checkpoint
molecules moonlight as regulatory molecules in bone remodeling
whereby costimulatory molecules (B7.1/7.2, B7–H2) inhibit, while
co-inhibitory molecules (B7–H3) stimulate osteoclastogenesis
[12, 13].
The role of B7–H3 in innate immune cells, which share the same
monocytic lineage as osteoclasts, remains controversial. In mouse-
derived BMMs, soluble B7–H3 (muB7–H3) stimulates NF-kB
activation and proinflammatory cytokine release, indicating that
B7–H3 exerts costimulatory effects on murine innate immune cells
[15]. In a previous study that showed the costimulatory effect of
B7–H3 in murine microglial cells, muB7–H3 was used as an
agonist, whereas a specific blocking antibody against B7–H3 was
used as an antagonist [16]. Conversely, B7–H3–Fc and
Y. Oh et al.
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B7–H3 siRNA both showed anti-osteoclastogenic effects in our
study, which is consistent with a previous study conducted in the
context of osteoblast differentiation [14]. The discrepancy of these
results may be explained in part by differences in experimental
model and/or design.
Type-I IFNs regulate osteoclastogenesis via several mechanisms,
including the inhibition of c-Fos and iNOS/NO signaling and
indirect inhibition of SOC1 and MITF through miR-155 induction
[17–20]. Our results suggest that mechanisms other than iNOS,
SOCS1, and c-Fos are responsible for mediating the effects of type-I
IFNs on osteoclastogenesis. Furthermore, our study implicates IDO,
which is an IFN-inducible gene in the regulation of osteoclastogen-
esis, suggesting that B7–H3 inhibits the type-I IFN–IDO pathway to
stimulate osteoclast differentiation. IDO acts either as a
tryptophan-degrading enzyme or an intracellular signal transducer
activated by transforming growth factor-β (TGF-β) [21–23]. Our
results suggest that AhR signaling is crucial for B7–H3-mediated
osteoclastogenesis inhibition. Notably, in our experiments, AhR
siRNA alone enhanced IDO expression in OCPs. Since AhR is known
to suppress STAT1 activity, AhR siRNA alone may have led to the
increase in IDO, which is a STAT1-dependent gene [24, 25].
Furthermore, the reason for the discrepancy between the AhR
siRNA experiment and the 1-MT and CH223191 experiments is
that kynurenine is only one of many endogenous AhR agonizts.
Consequently, 1-MT-mediated kynurenine inhibition may have
been insufficient to inhibit other endogenous AhR agonizts. Also,
CH223191, while known as an AhR inhibitor, is a ligand-selective
antagonist that preferentially inhibits agonizts of the halogenated
aromatic hydrocarbons (HAH). The action of endogenous AhR
ligands may not be inhibited by CH223191 as they are more likely
to bind AhR-like non-HAH agonizts [26]. Therefore, whether
CH223191 blocks the endogenous ligand activation of AhR needs
to be confirmed.
No significant bone-phenotypic changes were seen in B7–H3
KO mice in our study. The most likely hypothesis for this finding is
that B7–H3 KO has opposing effects on osteoclasts and
osteoblasts, such that there is no significant alteration in their
relative balance [14]. To directly test the causal relationship
between B7–H3 expression and osteoclast differentiation in vivo, a
genetic approach is required in which B7–H3 is specifically deleted
in myeloid-lineage OCPs. For example, using the experimental
model in which B7–H3-floxed mice are crossed with lysozyme
M-Cre mice may be appropriate. Nonetheless, in our in vitro study,
BMMs derived from B7–H3 KO mice showed lower osteoclasto-
genic potential and osteoclast-related gene expression, which
warrants this further experiment to observe bone-phenotypic
changes.
We show that unlike in PBMCs, B7–H3 knockdown does not
result in osteoclastogenesis inhibition in RA synovial-fluid
macrophages. This finding raises the possibility that the
B7–H3–IFN–IDO axis in healthy peripheral-blood OCPs is dysfunc-
tional in the RA synovium. We further showed that the
concentration of IFN-β capable of inducing IDO in healthy
peripheral blood OCPs does not induce IDO nor STAT1 activation
in RA synovial macrophages. This suggests that RA synovial
macrophages have an attenuated response to exogenous IFN-β,
which is consistent with many previous studies that have
established the attenuated responses of RA synovial macrophages
to inflammatory cytokines such as IL-6, -10, and -27 [27–30].
Therefore, further research focused on RA synovial macrophages is
necessary.
Various mechanisms mediate the immune-regulatory effects of
IDO [31]. In dendritic cells, B7.1/7.2 activates intracellular signaling
to induce IDO transcription and IDO-dependent immune tolerance
[32]. The function of B7 molecules is not limited to immune
regulation but also includes osteoclastogenesis regulation. Bozec
et al. demonstrated that RA patients treated with abatacept (CTLA-
4-Fc), which is approved for clinical use in RA, remarkably reduced
osteoclast precursors and downregulated osteoclast-
differentiation markers such as c-Fos, NFATc1, c-Fms, and RANK
[12]. Many clinical trials also show the bone-protective effect of
abatacept in RA, suggesting that in inflammatory bone-resorptive
disorders, B7 molecules represent a novel therapeutic avenue for
the development of anti-osteoclastogenic therapy.
Both B7.1/7.2- and CD200R1-mediated IDO induction depend
on type-I IFNs [33–35]. We showed that B7–H3 inhibition-
dependent IDO induction is also mediated by type-I IFNs. B7–H3
inhibition increases the production of anti-DNA autoantibodies
and exacerbates glomerulonephritis in lupus mouse models and
type-I IFNs are central to lupus pathogenesis [36, 37]. We further
observed that deletion of B7–H3 induces B7.1/7.2, suggesting that
B7–H3 inhibits B7.1/7.2-induced IDO expression in osteoclast
differentiation. Taken together with our findings showing that
B7–H3 inhibits type-I IFNs in human macrophages, the association
between B7–H3 inhibition and increased autoantibody production
and worsening glomerulonephritis may be mediated by type-I IFN
activation. Therefore, B7–H3 may inhibit type-I IFNs and disease
activity and has the therapeutic potential in patients with lupus.
A previously reported study established that B7–H3 is required
to induce bone mineralization and osteoblast differentiation [14].
Adding to this finding, we found that while trabecular bone mass
as assessed by micro-CT analysis is unaffected in B7–H3 KO mice,
mouse BMMs derived from these mice had reduced osteoclast
size. Thus, our investigation suggests that B7–H3 may be involved
in regulating the balance between osteoclast and osteoblast
formation.
Our study has several limitations. First, exogenous IFN-β and
B7–H3 inhibition both led to IDO induction, whereas IDO
Fig. 6 The inhibition of osteoclastogenesis is mediated by increased IDO expression in B7–H3-deficient OCPs. A M-CSF (40 ng/ml) was
added to monocyte culture for three days. OCPs that were transiently transfected with B7–H3-specific siRNA or control siRNA (40 nM) were
induced to differentiate using M-CSF (40 ng/ml) and RANKL (80 ng/ml) for seven days. B The M-CSF (40 ng/ml) was added in monocyte culture
for three days, then the cells were transfected with human pCMV3–B7–H3 ORF-expression plasmid or pCMV3-negative control vector (2 μg)
for one day. The expression of B7–H3, IDO, phospho-STAT1 (PY701), and STAT1 protein during osteoclast differentiation was analyzed by
Western blot. C OCPs that were transiently transfected with B7–H3-specific siRNA (20 nM), IDO-specific siRNA (60 nM), control siRNA (80 nM), or
both B7–H3- and IDO-specific siRNA were induced to differentiate using M-CSF (40 ng/ml) and RANKL (80 ng/ml) for seven days. The cells were
stained for TRAP expression and TRAP-positive multinucleated cells were counted as osteoclasts. Actin rings in osteoclasts stained with FITC-
phalloidin (scale bar, 200 μm). D The expression of mature osteoclast markers, CTSK, TRAP, DC-STAMP, and ITGB3, was analyzed using RT-qPCR.
The mRNA levels were normalized relative to GAPDH expression. E The expression of B7–H3, IDO, and NFATc1 protein was analyzed via
Western blot. F OCPs that were transiently transfected with B7–H3-specific siRNA or control siRNA (20 nM) were induced to differentiate using
M-CSF (40 ng/ml) and RANKL (80 ng/ml) in the presence of anti-IFN-αR2, -IFN-γ, or -IL-27 for three days. The expression of B7–H3, IDO,
phospho-STAT1 (PY701), and STAT1 protein was analyzed via Western blot. G Monocytes were treated with recombinant IFN-β (1 ng/ml) or
distilled water for one or two days. Whole-cell lysates were immunoblotted with IDO, phospho-STAT1 (PY701), and STAT1 antibodies. H OCPs
that were transiently transfected with IDO-specific siRNA or control siRNA (60 nM) were induced to differentiate using M-CSF (40 ng/ml) and
RANKL (80 ng/ml) in the presence of recombinant IFN-β (1 ng/ml) or distilled water for seven days. The cells were stained for TRAP expression
(scale bar, 200 μm). I At days 1 and 3, whole-cell lysates were immunoblotted with IDO, phospho-STAT1 (PY701), and STAT1 antibodies.
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knockdown led to reversal of osteoclastogenesis inhibition only in
the setting of B7–H3 inhibition and not exogenous IFN-β
administration. Second, the mechanism of IDO-mediated osteo-
clastogenesis inhibition in the setting of B7–H3 inhibition or
deficiency remains unknown. Third, the reason that B7–H3
deficiency does not lead to osteoclastogenesis inhibition in RA
synovial macrophages remains unclear. Fourth, the mechanism of
osteoclastogenesis inhibition in B7–H3 KO mice and the impact of
B7–H3 KO in specific disease-model mice remains unclear. Last,
the direct role of B7–H3 as a direct positive regulator of
osteoclastogenesis was not evaluated mainly because of the lack
of available B7–H3 agonizts since sB7–H3–Fc acted as an
antagonist in our experiments. Although our gain-of-function
study revealed that B7–H3 overexpression led to STAT1 inhibition
and STAT-1 dependent genes, the transient nature of B7–H3
overexpression precluded further assessment of the impact on
osteoclastogenesis. Future research is warranted in examining the
above questions to further elucidate the mechanism of B7–H3
inhibition in the negative regulation of osteoclastogenesis.
In conclusion, B7–H3 deficiency leads to inhibition of osteoclast
differentiation, and the type-I IFN–IDO pathway is an important
downstream-regulatory mechanism in B7–H3-mediated regulation
of osteoclastogenesis. Our study highlights B7–H3 as a strong
potential therapeutic target in human diseases in which B7–H3
Fig. 7 The inhibition of osteoclastogenesis is independent of the IDO/tryptophan pathway in B7–H3-deficient OCPs. A Monocytes were
cultured with M-CSF (20 ng/ml) for two days, then M-CSF (20 ng/ml) and RANKL (40 ng/ml) were added for an additional six days in the
presence of kynurenine (100 μM) or DMSO. B M-CSF (40 ng/ml) was added to monocyte culture for three days. OCPs that were transiently
transfected with B7–H3-specific siRNA or control siRNA (20 nM) were induced to differentiate using M-CSF (40 ng/ml) and RANKL (80 ng/ml)
for seven days with coadministration of 1-D-MT (200 μM), 1-L/D-MT (200 μM), or 0.1 N NaOH (control). C The experiment in (B) was conducted,
except with coadministration of tryptophan (1 mM) or distilled water (control). D The experiment in (B) was conducted, except with
coadministration of CH223191 (5 μM) or DMSO (control). E The OCPs that were transiently transfected with B7–H3-specific siRNA (20 nM), AhR-
specific siRNA (40 nM), control siRNA (60 nM), or both B7–H3- and AhR-specific siRNA were induced to differentiate using M-CSF (40 ng/ml)
and RANKL (80 ng/ml) for seven days. F Whole-cell lysates were immunoblotted with B7–H3, AhR, NFATc1, and IDO Abs. The bar graphs show
the densitometry analyses of the gels depicted relative to the internal control. (A, B, C, D, E) TRAP staining was performed and the number of
TRAP-positive multinucleated cells per well were counted as osteoclasts (scale bar, 200 μm).
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Fig. 8 B7–H3 deficiency does not affect osteoclast differentiation in RA synovial-fluid macrophages. A The expression of B7–H3 mRNA was
analyzed using RT-qPCR on human HC PBMCs and RA and AS synovial fluid macrophages. Monocytes were purified from PBMCs (n= 7), and
macrophages were derived from RA synovial-fluid mononuclear cells (n= 9) and AS synovial-fluid mononuclear cells (n= 6). The results are
shown as mean ± S.E.M. B The expression of B7–H3 protein between HC PBMCs and RA synovial-fluid macrophages (n= 3) was assessed by
Western blot. C M-CSF (40 ng/ml) was added to RA synovial-fluid macrophages for three days. OCPs that were transiently transfected with
B7–H3-specific siRNA or control siRNA (40 nM) were induced to differentiate using M-CSF (40 ng/ml) and RANKL (80 ng/ml) for seven days.
TRAP staining was performed and the number of TRAP-positive multinucleated cells per well were counted as osteoclasts (scale bar, 200 μm).
D The expression of the mature osteoclast markers, CTSK, TRAP, DC-STAMP, and ITGB3, and B7–H3, was analyzed by RT-qPCR. E, F The
expression of B7–H3, NFATc1, IDO, phospho-STAT1 (PY701), and STAT1 protein was evaluated using Western blot. G The expression of IFN-
inducible genes was analyzed using RT-qPCR at day 0. H HC PBMCs and RA synovial-fluid macrophages were treated with recombinant IFN-β
(1 ng/ml) for one or two days. Whole-cell lysates were immunoblotted with B7–H3, IDO, phospho-STAT1 (PY701), and STAT1 antibodies. (A, D,
G) The mRNA levels were normalized relative to GAPDH expression.
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type-I IFN–IDO-mediated regulation of immune responses and
osteoclast activation play important pathogenic roles.
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